{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:05:52Z","timestamp":1786982752557,"version":"build-2736575974"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,17]],"date-time":"2024-11-17T00:00:00Z","timestamp":1731801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,17]],"date-time":"2024-11-17T00:00:00Z","timestamp":1731801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003569","name":"Ministry of Food and Drug Safety","doi-asserted-by":"publisher","award":["21153MFDS607"],"award-info":[{"award-number":["21153MFDS607"]}],"id":[{"id":"10.13039\/501100003569","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s40259-024-00689-8","type":"journal-article","created":{"date-parts":[[2024,11,17]],"date-time":"2024-11-17T06:27:04Z","timestamp":1731824824000},"page":"143-152","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Effect of Biological Therapy for Psoriasis on the Development of Psoriatic Arthritis: A Population-Based Cohort Study"],"prefix":"10.1007","volume":"39","author":[{"given":"Yongtai","family":"Cho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suneun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyungyeon","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong-Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieun","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju Hwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1010-7525","authenticated-orcid":false,"given":"Ju-Young","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,17]]},"reference":[{"issue":"1","key":"689_CR1","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","volume":"80","author":"F Alinaghi","year":"2019","unstructured":"Alinaghi F, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):251-265.e19.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"689_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000588","volume":"3","author":"K Shah","year":"2017","unstructured":"Shah K, et al. Real-world burden of comorbidities in US patients with psoriatic arthritis. RMD Open. 2017;3(2): e000588.","journal-title":"RMD Open"},{"issue":"10136","key":"689_CR3","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","volume":"391","author":"DJ Veale","year":"2018","unstructured":"Veale DJ, Fearon U. The pathogenesis of psoriatic arthritis. Lancet. 2018;391(10136):2273\u201384.","journal-title":"Lancet"},{"issue":"18","key":"689_CR4","doi-asserted-by":"publisher","first-page":"adv00324","DOI":"10.2340\/00015555-3682","volume":"100","author":"I Lindberg","year":"2020","unstructured":"Lindberg I, et al. Incidence of psoriatic arthritis in patients with skin psoriasis and associated risk factors: a retrospective population-based cohort study in swedish routine clinical care. Acta Derm Venereol. 2020;100(18):adv00324.","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"689_CR5","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","volume":"80","author":"A Menter","year":"2019","unstructured":"Menter A, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029\u201372.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"689_CR6","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1111\/jdv.16915","volume":"34","author":"A Nast","year":"2020","unstructured":"Nast A, et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris\u2014part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol. 2020;34(11):2461\u201398.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10275","key":"689_CR7","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/S0140-6736(21)00184-7","volume":"397","author":"K Ghoreschi","year":"2021","unstructured":"Ghoreschi K, Balato A, Enerb\u00e4ck C, Sabat R. Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet. 2021;397(10275):754\u201366.","journal-title":"Lancet"},{"issue":"4","key":"689_CR8","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1002\/art.40778","volume":"71","author":"L Savage","year":"2019","unstructured":"Savage L, et al. Regression of peripheral subclinical enthesopathy in therapy-naive patients treated with ustekinumab for moderate-to-severe chronic plaque psoriasis: a fifty-two-week, prospective, open-label feasibility study. Arthritis Rheumatol. 2019;71(4):626\u201331.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"689_CR9","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1002\/art.41946","volume":"74","author":"YS Rosenthal","year":"2022","unstructured":"Rosenthal YS, Schwartz N, Sagy I, Pavlovsky L. Incidence of psoriatic arthritis among patients receiving biologic treatments for psoriasis: a nested case-control study. Arthritis Rheumatol. 2022;74(2):237\u201343.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"689_CR10","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1136\/annrheumdis-2021-220865","volume":"81","author":"ML Acosta Felquer","year":"2022","unstructured":"Acosta Felquer ML, et al. Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis. Ann Rheum Dis. 2022;81(1):74\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"689_CR11","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1136\/annrheumdis-2021-219961","volume":"81","author":"P Gisondi","year":"2022","unstructured":"Gisondi P, et al. Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis. Ann Rheum Dis. 2022;81(1):68\u201373.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"689_CR12","doi-asserted-by":"publisher","first-page":"e200","DOI":"10.1016\/S2665-9913(23)00034-6","volume":"5","author":"S Singla","year":"2023","unstructured":"Singla S, Putman M, Liew J, Gordon K. Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study. Lancet Rheumatol. 2023;5(4):e200\u20137.","journal-title":"Lancet Rheumatol"},{"issue":"2","key":"689_CR13","doi-asserted-by":"publisher","first-page":"115","DOI":"10.5021\/ad.2020.32.2.115","volume":"32","author":"SP Ham","year":"2020","unstructured":"Ham SP, et al. Validity of diagnostic codes for identification of psoriasis patients in Korea. Ann Dermatol. 2020;32(2):115\u201321.","journal-title":"Ann Dermatol"},{"issue":"5","key":"689_CR14","first-page":"308","volume":"56","author":"M Lee","year":"2018","unstructured":"Lee M, Lee JW, Kim TG, Lee MG. Clinical features and treatment patterns of Korean patients with psoriatic arthritis: a retrospective single-center study. Korean J Dermatol. 2018;56(5):308\u201313.","journal-title":"Korean J Dermatol"},{"issue":"9","key":"689_CR15","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.3899\/jrheum.201199","volume":"48","author":"P Karmacharya","year":"2021","unstructured":"Karmacharya P, et al. Diagnostic delay in psoriatic arthritis: a population-based study. J Rheumatol. 2021;48(9):1410\u20136.","journal-title":"J Rheumatol"},{"key":"689_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2021.12.013","volume":"52","author":"P Karmacharya","year":"2022","unstructured":"Karmacharya P, et al. Time to transition from psoriasis to psoriatic arthritis: a population-based study. Semin Arthritis Rheum. 2022;52: 151949.","journal-title":"Semin Arthritis Rheum"},{"issue":"23","key":"689_CR17","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1001\/jama.2020.7819","volume":"323","author":"LE Thomas","year":"2020","unstructured":"Thomas LE, Li F, Pencina MJ. Overlap weighting: a propensity score method that mimics attributes of a randomized clinical trial. JAMA. 2020;323(23):2417\u20138.","journal-title":"JAMA"},{"issue":"10","key":"689_CR18","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s40266-019-00688-3","volume":"36","author":"F Caso","year":"2019","unstructured":"Caso F, et al. Late-onset and elderly psoriatic arthritis: clinical aspects and management. Drugs Aging. 2019;36(10):909\u201325.","journal-title":"Drugs Aging"},{"issue":"9","key":"689_CR19","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/s41584-022-00810-7","volume":"18","author":"S Tarannum","year":"2022","unstructured":"Tarannum S, et al. Sex- and gender-related differences in psoriatic arthritis. Nat Rev Rheumatol. 2022;18(9):513\u201326.","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"689_CR20","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1080\/10543406.2020.1757692","volume":"30","author":"G Dong","year":"2020","unstructured":"Dong G, et al. The inverse-probability-of-censoring weighting (IPCW) adjusted win ratio statistic: an unbiased estimator in the presence of independent censoring. J Biopharm Stat. 2020;30(5):882\u201399.","journal-title":"J Biopharm Stat"},{"issue":"3","key":"689_CR21","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1093\/aje\/kwy263","volume":"188","author":"K Yoshida","year":"2019","unstructured":"Yoshida K, et al. Multinomial extension of propensity score trimming methods: a simulation study. Am J Epidemiol. 2019;188(3):609\u201316.","journal-title":"Am J Epidemiol"},{"issue":"24","key":"689_CR22","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1001\/jama.2016.17700","volume":"316","author":"BF Arnold","year":"2016","unstructured":"Arnold BF, Ercumen A. Negative control outcomes: a tool to detect bias in randomized trials. JAMA. 2016;316(24):2597\u20138.","journal-title":"JAMA"},{"issue":"4","key":"689_CR23","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","volume":"167","author":"TJ VanderWeele","year":"2017","unstructured":"VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the e-value. Ann Intern Med. 2017;167(4):268\u201374.","journal-title":"Ann Intern Med"},{"issue":"1","key":"689_CR24","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1136\/annrheumdis-2021-220761","volume":"81","author":"E Meer","year":"2022","unstructured":"Meer E, et al. Does biologic therapy impact the development of PsA among patients with psoriasis? Ann Rheum Dis. 2022;81(1):80\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"689_CR25","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2174\/187152812800392805","volume":"11","author":"E Toussirot","year":"2012","unstructured":"Toussirot E. The IL23\/Th17 pathway as a therapeutic target in chronic inflammatory diseases. Inflamm Allergy Drug Targets. 2012;11(2):159\u201368.","journal-title":"Inflamm Allergy Drug Targets"},{"issue":"5","key":"689_CR26","doi-asserted-by":"publisher","first-page":"R96","DOI":"10.1186\/ar2297","volume":"9","author":"T Yago","year":"2007","unstructured":"Yago T, et al. IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats. Arthritis Res Ther. 2007;9(5):R96.","journal-title":"Arthritis Res Ther"},{"key":"689_CR27","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.3389\/fimmu.2019.02740","volume":"10","author":"H Fuseini","year":"2019","unstructured":"Fuseini H, et al. ER\u03b1 signaling increased IL-17A production in Th17 cells by upregulating IL-23R expression, mitochondrial respiration, and proliferation. Front Immunol. 2019;10:2740.","journal-title":"Front Immunol"},{"issue":"1","key":"689_CR28","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1084\/jem.20030451","volume":"199","author":"E Lee","year":"2004","unstructured":"Lee E, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med. 2004;199(1):125\u201330.","journal-title":"J Exp Med"},{"issue":"2","key":"689_CR29","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/bjd.18634","volume":"183","author":"J Diels","year":"2020","unstructured":"Diels J, et al. Adjusted treatment COMPArisons between guSelkumab and uStekinumab for treatment of moderate-to-severe plaque psoriasis: the COMPASS analysis. Br J Dermatol. 2020;183(2):276\u201384.","journal-title":"Br J Dermatol"},{"issue":"16","key":"689_CR30","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1056\/NEJMoa1607017","volume":"376","author":"KA Papp","year":"2017","unstructured":"Papp KA, et al. Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis. N Engl J Med. 2017;376(16):1551\u201360.","journal-title":"N Engl J Med"},{"issue":"1","key":"689_CR31","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jaad.2020.04.139","volume":"84","author":"S Mehrmal","year":"2021","unstructured":"Mehrmal S, et al. The global, regional, and national burden of psoriasis in 195 countries and territories, 1990 to 2017: a systematic analysis from the Global Burden of Disease Study 2017. J Am Acad Dermatol. 2021;84(1):46\u201352.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"689_CR32","doi-asserted-by":"publisher","first-page":"e003423","DOI":"10.1136\/rmdopen-2023-003423","volume":"10","author":"PJ Mease","year":"2024","unstructured":"Mease PJ, et al. Evaluating the efficacy of biologics with and without methotrexate in the treatment of psoriatic arthritis: a network meta-analysis. RMD Open. 2024;10(1):e003423.","journal-title":"RMD Open"},{"issue":"5","key":"689_CR33","first-page":"CD011535","volume":"5","author":"E Sbidian","year":"2022","unstructured":"Sbidian E, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2022;5(5):CD011535.","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"689_CR34","doi-asserted-by":"publisher","first-page":"3410","DOI":"10.1007\/s12325-023-02568-0","volume":"40","author":"A Blauvelt","year":"2023","unstructured":"Blauvelt A, Chiricozzi A, Ehst BD, Lebwohl MG. Safety of IL-23 p19 inhibitors for the treatment of patients with moderate-to-severe plaque psoriasis: a narrative review. Adv Ther. 2023;40(8):3410\u201333.","journal-title":"Adv Ther"},{"issue":"5","key":"689_CR35","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/jamadermatol.2022.0364","volume":"158","author":"L Pina Vegas","year":"2022","unstructured":"Pina Vegas L, Penso L, Claudepierre P, Sbidian E. Long-term persistence of first-line biologics for patients with psoriasis and psoriatic arthritis in the French Health Insurance Database. JAMA Dermatol. 2022;158(5):513\u201322.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"689_CR36","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jaad.2019.05.064","volume":"82","author":"E Cozzani","year":"2020","unstructured":"Cozzani E, et al. Serial biologic therapies in psoriasis patients: a 12-year, single-center, retrospective observational study. J Am Acad Dermatol. 2020;82(1):37\u201344.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"689_CR37","doi-asserted-by":"publisher","first-page":"2200870","DOI":"10.1080\/09546634.2023.2200870","volume":"34","author":"AW Armstrong","year":"2023","unstructured":"Armstrong AW, et al. Real-world switching patterns and associated characteristics in patients with psoriasis treated with biologics in the United States. J Dermatol Treat. 2023;34(1):2200870.","journal-title":"J Dermatol Treat"},{"key":"689_CR38","unstructured":"HIRA. Detailed criteria and methods for the application of medical care benefits (pharmaceuticals). 2022. https:\/\/www.hira.or.kr\/ebooksc\/ebook_700\/ebook_700_202209050304316930.pdf."},{"issue":"1","key":"689_CR39","doi-asserted-by":"publisher","first-page":"4139","DOI":"10.1038\/s41598-024-54447-5","volume":"14","author":"H Jung","year":"2024","unstructured":"Jung H, Kim SR, Cho SI, Jo SJ. Reduced economic disparity in biologics use for psoriasis after introducing the reducing copayment program. Sci Rep. 2024;14(1):4139.","journal-title":"Sci Rep"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-024-00689-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-024-00689-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-024-00689-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T16:24:25Z","timestamp":1737476665000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-024-00689-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,17]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["689"],"URL":"https:\/\/doi.org\/10.1007\/s40259-024-00689-8","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,17]]},"assertion":[{"value":"29 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by a grant (21153MFDS607) from the Ministry of Food and Drug Safety of South Korea. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"J.Y.S. received grants from the Ministry of Food and Drug Safety, the Ministry of Health and Welfare, the National Research Foundation of Korea, and pharmaceutical companies, including Pfizer, UCB, and Yuhan, outside the submitted work. No other relationships or activities have influenced the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interests"}},{"value":"All authors contributed to the study conception and design. K.J. and J.Y.S. carried out material preparation and data collection; Y.C. and J.L. carried out data analysis; Y.C. wrote the first draft of the manuscript and all authors commented on previous versions of the manuscript. All authors contributed to the interpretation of the data and approved the final manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"Data used in this study are obtainable by services provided by the Health Insurance Review and Assessment, but restrictions may apply to the availability of these data, which were used under the license for the current study, and so are not publicly available.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"This study was approved by the institutional review board of Sungkyunkwan University, South Korea (SKKU 2023-10-020)","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}